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Abstract
Background: Resistant starch (RS) is a type of dietary fiber that can improve glucose metabolism, but its effects may
be modulated by sex or baseline insulin sensitivity. This study was designed to examine the effect of high-amylose
maize resistant starch (HAM-RS2) on insulin sensitivity (SI) in women, and to determine if SI status affects the response
to RS.
Methods: This was a randomized, placebo-controlled, double-blind, cross-over study. Participants were 40 healthy,
non-diabetic women aged 22–67 years in the normal-weight to obese BMI range (20.6–47.4 kg/m2). Two doses of
HAM-RS2 were tested, 15 and 30 g per day, administered in the form of cookies. Participants were randomized to the
order in which they received the experimental and placebo product. Each arm was 4 weeks, with a 4-week wash-out
period in between. SI was assessed at the end of each 4-week arm of product consumption by frequently-sampled,
insulin-modified, intravenous glucose tolerance test and minimal modeling. Participants were categorized as being
insulin resistant (IR; SI < 7.8) or insulin sensitive (IS; SI≥ 7.8) based on Gaussian analysis. The effect of treatment arm on
SI was examined by mixed-model analysis within IR and IS sub-groups, using all available data. In addition, SI was
examined by ANOVA among just those women who completed all three arms of the study with valid SI results.
Results: Among IR participants, SI was on average ~16 % higher after the 30 g arm when compared to the control
arm by mixed-model analysis (n = 40, P < 0.05), and tended to be 23 % higher by ANOVA among women who
completed all arms (n = 23, P = 0.06). HAM-RS2 did not affect SI in IS women.
Conclusion: Consumption of HAM-RS2 at 30 g/day in the form of a snack food item was associated with improved
insulin sensitivity in women with insulin resistance.
Clinical trials registry number: NCT01521806.
Keywords: Minimal model, Intravenous glucose tolerance test
Background
Resistant starch (RS) is a type of dietary fiber that has
beneficial effects on insulin sensitivity and gastrointes-
tinal health in humans [1]. By definition, RS is a type of
carbohydrate that is incompletely digested by human
pancreatic amylases. As a result, the starch molecules
are cleaved in the colon by bacterial enzymes and
subsequently metabolized as fuel by the gut microbiota.
Four types of RS have been identified. Type 2, which is
found in some starchy foods such as green bananas,
potatoes, and high-amylose corn, has been investigated
most extensively for its effects on human health.
It is thought that the insulin-sensitizing effects of RS
are due in part to the short-chain fatty acids that result
from bacterial metabolism of the carbohydrate mole-
cules [2]. Administration of exogenous short-chain fatty
acids results in suppression of circulating free fatty acids
by limiting lipolysis [3]. Because elevated fatty acids are
associated with both suppression of insulin-stimulated
* Correspondence: bgower@uab.edu
1Department of Nutrition Sciences, University of Alabama at Birmingham
(UAB), 616A Webb Building, 1675 University Blvd, Birmingham, AL 35294,
USA
Full list of author information is available at the end of the article
© 2016 Gower et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Gower et al. Nutrition & Metabolism  (2016) 13:2 
DOI 10.1186/s12986-016-0062-5
glucose uptake at skeletal muscle [4] and inhibition of
insulin suppression of glycogenolysis at the liver [5],
their reduction may improve insulin sensitivity. It is also
possible that RS increases adiponectin, an adipocyte-
derived hormone with insulin sensitizing properties. In
mice, RS increases adipose tissue adiponectin concentra-
tions [6], and in humans, greater intake of cereal fiber is
associated with greater circulating adiponectin [7, 8].
Clinical studies documenting effects of RS on insulin
sensitivity have generally yielded positive results. Acute
consumption of 60 g RS over 24 h resulted in 69 %
higher insulin sensitivity by mixed-meal tolerance test in
a group of 10 healthy men and women [9]. Consumption
of type 2 RS for 4 weeks at a dose of 30 g/day was asso-
ciated with a 33 % increase in insulin sensitivity as
assessed with mixed-meal tolerance test, and a 14 % in-
crease as assessed by euglycemic clamp in a group of 10
healthy men and women [10]. Consumption of 40 g/d
RS led to a 16 % increase in insulin sensitivity by eugly-
cemic clamp in a group of 20 insulin resistant men and
women [11]. Consumption of both 15 and 30 g/d RS for
4 weeks was associated with increased insulin sensitivity
(48 and 53 %, increase in mean values, respectively) as
assessed with intravenous glucose tolerance test in a
group of 11 overweight/obese men [12]. However, in the
same study, no effect was observed in a group of 22
women, leading to a significant treatment-by-sex effect
(P < 0.05). Although the explanation for this sex differ-
ence was not known, it was speculated that failure to
control for menstrual cycle phase, or higher insulin sen-
sitivity in women vs men [13, 14], may have played a
role.
This study was designed to examine the effect of high-
amylose maize resistant starch (HAM-RS2) administered
as a snack food on insulin sensitivity (SI) in women, con-
trolling for menstrual cycle phase, and to determine if SI
status (high vs low) affects the response to RS.
Methods
Participants were healthy, sedentary women. Exclusion
criteria included type 1 or type 2 diabetes, polycystic
ovary syndrome, disorders of glucose or lipid metabol-
ism, hypertension, use of medication that could affect
glucose metabolism (including non-approved oral con-
traceptives and postmenopausal hormone replacement
therapy), use of tobacco, alcohol consumption in excess
of 400 grams per week, engagement in more than 2 h
intentional moderate or light exercise per week, and a
medical history that counter-indicated inclusion in the
study. Women were categorized as premenopausal if
they experienced regular menstrual cycles, and postmen-
opausal if they were over age 50 and had not had a cycle
in the past 12 months. One woman aged 53 reported
irregular menstrual cycles; she was categorized as peri-
menopausal and coded with the premenopausal group
for statistical analyses. Premenopausal women were per-
mitted to use tri-phasic, low-dose oral contraceptives.
Because one goal of the study was to determine if base-
line insulin sensitivity status affected the response to RS,
an effort was made to recruit African-American women,
who are more insulin resistant than Caucasian women,
even when obesity status and fat distribution are
accounted for [15, 16]. Thus, including both African-
American and Caucasian women would increase the
likelihood of having a wide range of values for insulin
sensitivity. Participants were informed of the experimen-
tal design, and oral and written consent were obtained.
The study was approved by the Institutional Review
Board for Human Use at the University of Alabama at
Birmingham (UAB).
The study was conducted using a randomized,
placebo-controlled, double-blind cross-over design.
Two doses of resistant starch were tested, 15 and 30 g
per day, administered in the form of crackers, and van-
illa- and lemon-flavored cookies. Within the first two
months of the trial, subjects indicated a dislike for the
crackers, and the study continued with cookies only.
The resistant starch was a type 2, granular, form from
high-amylose maize (HAM-RS2). A control snack was
formulated with a highly digestible waxy corn starch to
match the amount of digestible starch provided by the
HAM-RS2 in the 15 g snack (~11.6 g/d). The cookies
were tested to verify macronutrient, fiber, and RS con-
tent (Table 1). Each arm was 4 weeks, with a 4-week
wash-out period between. Test products were adminis-
tered in random order. For all arms, participants were
asked to consume two servings of test product per day
(28–47 g per serving, depending upon the snack type
and starch dose). Participants reported to the clinic
weekly where they were weighed, met with the dietitian,
and picked up product. If they missed a pickup, they
were queried regarding their product use during the
interim. If participants missed more than 2 days of
product use, they either started over with that particu-
lar arm, or were removed from the study. Habitual diet
was monitored via 4-day food records obtained at base-
line and during each of the three test phases, analyzed
with Nutrition Data Systems for Research (NDSR
2012). For premenopausal women, testing was con-
ducted in the first 10 days of the follicular phase of the
menstrual cycle. Anthropometrics were collected at
baseline and after each arm. Height and weight were
assessed using an electronic scale and a wall-mounted
stadiometer. Waist circumference was measured
around the narrowest portion of the torso with a flex-
ible tape.
Insulin sensitivity was assessed by insulin-modified,
frequently-sampled intravenous glucose tolerance test
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(IVGTT) and Minimal Model analyses [17–19]. Testing
was conducted in the Clinical Research Unit of UAB’s
Center for Clinical and Translational Science (CCTS)
after an overnight fast. Prior to testing, flexible intraven-
ous catheters were placed in the antecubital spaces of
both arms. Three, 2.0 ml blood samples were taken over
a 20-min period for determination of basal glucose and
insulin (the average of the values was used for basal
“fasting” concentrations). At time “0”, glucose (50 %
dextrose; 300 mg/kg) was administered intravenously
over 2 min. Insulin (0.02 U/kg, Humulin, Eli Lilly and
Co., Indianapolis) was infused from 20 to 25 min post
glucose injection. Blood samples (2.0 ml) were then col-
lected at the following times (min) relative to glucose
administration: 2, 3, 4, 5, 6, 8, 10, 12, 15, 19, 20, 21, 22,
24, 26, 28, 30, 35, 40, 45, 50, 55, 60, 70, 80, 100, 120,
140, 180, 210, 240.
Sera were stored at -85 °C until analyzed. Glucose and
insulin values were entered into the MINMOD com-
puter program (Millennium version, © Richard N.
Bergman [19]) for determination of the insulin sensitiv-
ity index (SI). The acute insulin response to glucose
(AIRg) was calculated by the software as the incremental
insulin area-under-the-curve from minutes 0–10 follow-
ing glucose injection using the trapezoidal method.
Disposition Index (DI) was calculated as SI x AIRg, a
composite measure of insulin secretion and insulin
sensitivity. Glucose effectiveness (SG) also was generated
by the model; SG describes the extent to which glucose
uptake is stimulated, and glucose production inhibited,
by glucose itself, independent of a dynamic change in
insulin.
Laboratory analyses were conducted in the Core
Laboratory of the CRU, Nutrition Obesity Research
Center, and Diabetes Research Center. Glucose, total
cholesterol, HDL-cholesterol, and triglycerides were
measured using a SIRRUS analyzer (Stanbio Laboratory,
Boerne, TX). Insulin was assayed by immunofluores-
cence on a TOSOH AIA-II analyzer (TOSOH Corp.,
South San Francisco, CA); intra-assay CV of 1.5 % and
inter-assay CV of 4.4 %. Adiponectin was assessed by
radioimmunoassay (Linco-Millipore; Billerica, MA);
inter-assay CV was 9.98 %; intra-assay CV was 4.70 %;
and sensitivity (90 % bound) was 1.0 μg/ml.
IR women were identified using histogram analysis of
SI values from all valid tests, and univariate normal mix-
ture decomposition analysis. Two subgroups were noted,
with the majority of observations belonging to a distri-
bution with a mean of 4.1 and a SD of 1.9. A cut-point
for IR was established at 7.8 based on the estimated SD
for this group, which was two standard deviations from
the observed mean (upper limit on the 95 % confidence
interval, Fig. 1). Thus, for subsequent analyses, partici-
pants were categorized as being either IR (SI < 7.8) or
insulin sensitive (IS; SI ≥ 7.8). Eight women in the group
who completed all three phases of the study had at least
one SI measure ≥7.8.
Data were analyzed by mixed-effects modeling within
each subgroup (IR/IS), with waist circumference and
completer status as covariates, subject ID as a group
variable, and both test doses of RS contrasted against
the placebo treatment. The mixed model considers all
data, and thus allowed for inclusion of data from women
who completed only one or two arms of the study. To
confirm that the results obtained with the mixed model
were valid within women who completed all three arms
of the study, results also were analyzed by repeated-
measures ANOVA and Student-Newman-Keuls pairwise
comparisons within only those women who had valid SI
tests for all three arms (n = 23). Descriptive information
was compared by ANOVA between IR and IS sub-
groups using the Dose = 0 data. Ancillary, exploratory,
analyses were conducted within sub-groups based on
menopausal status and race/ethnicity. Due to small
Table 1 Ingredient list and composition of test cookiesa
Control 15 g RS 30 g RS
Ingredients (g/100 g)
All-purpose flour 24.8 16.5 0.8
Wheat gluten 7.9 4.7 3.9
Sunflower oil 8.2 5.9 4.3
Salt 0.09 0.08 0.08
Sugar 13.3 13.4 12.9
Lemon extract 2.1 2.1 2.1
Whole eggs 10.3 10.5 10.7
Baking powder 0.4 0.4 0.4
Water 9.3 11 14.8
Dry milk 7.4 7.4 7.6
Waxy corn starchb 16.1 0 0
HAM-RS2c 0 27.7 42.2
Composition (post-baking)
Portion size (g) 28.4 36.7 46.3
Energy (kcal)d 126.9 129.6 138.2
Carbohydrate (g)d 18.5 19.2 20.8
Protein (g)d 4.7 4.6 5.0
Fat (g)d 3.8 3.8 3.9
Dietary fiber (g)d 0.5 7.8 14.8
Resistant starch (g)e 3.18 11.35 19.05
a Cookies produced by International Food Network, Ithaca, NY. Data shown are
for lemon-flavored cookies. Vanilla-flavored cookies were of similar formulation
and composition (<3 % variation in composition between types of cookies;
data not shown). Two servings of cookies were consumed per day
bAMIOCA® corn starch, Ingredion Incorporated, Bridgewater, NJ
c HI-MAIZE® 260 resistant starch, Ingredion Incorporated, Bridgewater, NJ
d Composite analyses performed by Medallion Labs, Minneapolis, MN; Dietary
fiber determined using AOAC method 991.43
e Resistant starch estimated using a modified Englyst RS assay
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sample sizes in these sub-groups, paired t-test was used
to explore differences in SI among the three RS doses.
For all analyses, P < 0.05 was considered significant.
Results
Fifty-one women entered the study (Fig. 2), and 43
completed the first phase of the study, 40 of whom had
a usable SI result. For mixed-model analysis, data from
these 40 women were used. The mean age of this sample
at baseline was 48.3 ± 12.6 years; mean BMI was 29.8 ±
6.7 kg/m2. Eighteen women were pre- or peri-menopausal;
22 were postmenopausal. The ethnic composition was 24
non-Hispanic Caucasian, 14 African-American, and 2
Hispanic. Twelve women had at least one SI measure >7.8;
all were Caucasian. Twenty-five women completed all
three phases of the study; of these, 24 had usable SI results.
Seven insulin sensitivity tests were not available for issues
relating to iv access or scheduling. Reasons for discontinu-
ing the study included difficulty with the time commit-
ment, transportation problems, and unwillingness to
consume the snacks as directed. Data from one woman
were excluded due to IVGTT results indicating undiag-
nosed diabetes. For ANOVA, data from the 23 non-
diabetic women who completed all three phases of the
study and had usable SI results were used. The mean age
of this sample at baseline was 52.4 ± 12.0 year. Seven
women were pre- or peri-menopausal; 14 were postmeno-
pausal. The ethnic composition was 17 non-Hispanic
Caucasian and 6 African-American. All IS women were
Caucasian, and all African-American women were in the
IR group. The IR group contained 4 pre-and 10 post-
Fig. 1 Gaussian distributions of insulin sensitivity values. Two groups [(insulin resistant (IR) and insulin sensitive (IS)] were identified based on the
cut-point of 7.8
Fig. 2 Consort diagram depicting participant numbers throughout
recruitment and testing
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menopausal women. The IS group contained 3 pre- and 6
post-menopausal women.
Thirty-one women completed food records during at
least one arm of the study, for a total of 68 records. Ana-
lysis of diet data indicated that, on average, habitual diet
did not change across the three arms of the study, and
was not different between the IR and IS sub-groups for
any treatment arm. Combined average intake of total
energy was 1665 ± 496 kcal/day; %energy from carbohy-
drates, protein, and fat was 45.7 ± 7.1, 16.4 ± 3.8, and
35.9 ± 5.0, respectively. Intake of dietary fiber (g/day; not
including the experimental product) was not different
across treatment arms. However, daily intake of total
dietary fiber was significantly and consistently lower in
the IR vs the IS women across the entire course of the
study: Dose = 0 g/day (13.9 ± 4.1 vs 18.0 ± 4.4, P < 0.05);
Dose = 15 g/day (14.0 ± 6.6 vs 21.3 ± 1.0, P < 0.05); and
Dose = 30 g/day (13.4 ± 3.7 vs 19.0 ± 5.9, P < 0.01).
When considering the entire group of 40 women who
completed at least one arm of the study, mixed model
analysis among IR participants (n = 28) revealed a signifi-
cant impact of the 30 g dose of RS (P < 0.05; Table 2,
Fig. 3). Predicted values (Mean ± SEM) by dose were 0:
4.07 ± 0.18; 15: 4.02 ± 0.19; 30: 4.70 ± 0.23. No effect of
either RS dose was observed among IS participants (n =
12). No carryover effects were detected.
Data from those women who completed all three arms
of the study are shown in Table 3, by IR/IS status, at the
end of each study arm. On average, IR women had
higher concentrations of fasting glucose and insulin than
IS women (at dose = 0). Waist circumference at dose = 0
(n = 18) averaged 99.2 ± 12.2 in the IR sub-group, and
90.7 ± 12.3 in the IS sub-group (P = 0.184). Body weight
at dose = 0 was higher in the IR group (86.8 ± 16.6 kg)
than in the IS group (67.0 ± 8.0 kg) (P < 0.01). BMI at
dose = 0 was higher in the IR group (32.9 ± 7.3 kg/m2)
than in the IS group (25.6 ± 3.4 kg/m2) (P < 0.05).
ANOVA within the IR sub-group indicated a significant
main effect (P < 0.05) of “Dose” on SI. Post-hoc compari-
son among doses indicated that the 30 g/day dose differed
from the 15 g/day dose (P < 0.05); the comparison of the
30 and 0 g doses approached significance (P = 0.068). No
dose effect was observed within the IS sub-group. Further
analyses indicated that the significant effect of RS was
confined to the postmenopausal women (34 % higher after
30 g RS vs 0 g RS, P < 0.05). When secondary outcomes
were examined within the IR sub-group, the Disposition
Index (DI; P < 0.05) and AIRg (p = 0.056) were higher with
the 30 g/day dose compared to the 15 g/day dose. No
differences were observed within the IS sub-group.
Discussion
The primary finding from this study was that 30 g/d of
RS in the form of a snack food led to greater insulin sen-
sitivity among IR women, a group that included all of
the African-American women in the study. These results
extend observations from clinical studies involving sam-
ples of healthy men and women combined, men and
women with metabolic syndrome, and overweight/obese
men, among whom beneficial effects of RS on insulin
sensitivity have been detected. Importantly, results from
this study may explain the significant treatment-by-sex
interaction observed previously [12], where RS treatment
increased insulin sensitivity in obese men but not
women. Based on the present results, we tentatively con-
clude that RS is most effective in insulin resistant
populations.
One of the major findings of the study was that an effect
of baseline insulin sensitivity was detected, such that RS
treatment improved insulin sensitivity among IR but not
IS women. The IR group included all of the African-
American women enrolled in the study. In contrast, the IS
group was exclusively Caucasian. African-Americans are
at disproportionate risk for type 2 diabetes, and we have
previously reported that SI is lower in African-Americans
Fig. 3 Insulin sensitivity (SI; mean ± SEM) by dose at the end of each
4-week arm within insulin resistant women (n = 28). *Dose = 30 g/
day differed from Dose = 0 g/day (P < 0.05) by mixed-model analysis.
Means ± SEM were 0: 4.07 ± 0.18; 15: 4.02 ± 0.19; 30: 4.70 ± 0.23
Table 2 Mixed-effects model for the dependent variable SI
a
within all IR women in the study (SI < 7.8; n = 28)
Coefficient SEM P 95 % CI
15 g/d 0.31 0.36 0.38 -0.39–1.01
30 g/d 0.87 0.38 0.02 0.12–1.62
Completer statusb 0.65 0.51 0.20 -0.34–1.65
Waist circumference -0.07 0.02 0.00 -0.11–0.03
Constant 10.20 1.86 0.00 6.56–13.83
SI insulin sensitivity
aSI was obtained after 4 weeks of treatment with 0, 15 g, or 30 g RS/day.
Subject ID was included as a group variable
bParticipants were coded “0” if they completed one or two arms, or “1” if they
completed all three arms of the study
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when compared to Caucasians [15, 16]. We also observed
that the effect of RS on SI was significant only within the
postmenopausal women in the IR sub-group. In these
women, a significant (P < 0.05) 34 % increase in SI
occurred between the 0 and 30 g/day doses. After meno-
pause, women experience increases in risk for several
metabolic diseases including type 2 diabetes and cardio-
vascular disease [20, 21]. Although further studies with
larger samples are needed before conclusions can be
drawn, results of this study suggest that RS may be par-
ticularly effective at improving insulin sensitivity in
African-Americans and post-menopausal women, groups
that are at elevated risk for chronic metabolic disease.
We noted that the IR sub-group, on average, consumed
23–33 % less dietary fiber than did the IS sub-group. Fur-
ther, in all women combined, dietary fiber intake was posi-
tively associated with insulin sensitivity (r = 0.28, P < 0.05)
in a simple correlation analysis (data not shown). Al-
though these results must be treated with caution because
compliance with food record submission was incomplete,
it is possible that lower insulin sensitivity in the IR sub-
group was due at least in part to habitually lower fiber
consumption. It is also possible that the lack of effect of
the RS treatment on insulin sensitivity in the IS sub-group
was due to their greater habitual consumption of dietary
fiber.
Although two doses of RS (15 and 30 g/day) were tested
in this study, the effect of RS was significant only with the
30 g/day dose. In contrast, within abdominally obese men,
consumption of both 15 and 30 g/d RS for 4 weeks
resulted in higher mean SI [12]. The IR women in this
study had a waist circumference of ~99 cm on average, a
value that corresponds to a visceral fat area of >130 cm2,
the threshold for perturbations in glucose-insulin homeo-
stasis [22]. Nonetheless, these women were relatively
healthy. It is possible that a cohort of women with greater
metabolic dysfunction would have responded to the lower
dose of RS. It is also possible that women are less respon-
sive to RS, and therefore require a higher dose.
In this study, IR women exhibited greater insulin
sensitivity after the 30 g/d treatment compared to pla-
cebo. This insulin sensitivity was at the “whole body”
level; i.e., the Minimal Model SI value includes both
insulin-stimulated glucose uptake at skeletal muscle and
insulin inhibition of hepatic glucose production. Thus,
we cannot determine whether RS treatment affected
skeletal muscle, liver, or both. A previous study that used
a tracer-based euglycemic clamp indicated that RS af-
fected skeletal muscle and adipose tissue but not hepatic
insulin sensitivity in insulin resistant participants [3].
Nonetheless, several studies have reported lower fasting
glucose and/or insulin, markers of hepatic insulin sensi-
tivity, following treatment with RS [3, 23]. Further, the
effect of RS on whole-body insulin sensitivity is relatively
large (e.g., 33–69 % observed with meal tolerance test or
intravenous glucose tolerance test [9, 10, 12]) in contrast
to the 14–16 % improvement observed with the muscle-
specific euglycemic clamp [10, 11]. Studies are needed to
Table 3 Biochemical and metabolic measures of the 23 women who completed all arms of the study by insulin sensitivity sub-
group (IR/IS) after 4 weeks of exposure to the indicated dose of RS. Mean (SD)
IR (n = 14) IS (n = 9)
RS dose (g/day) RS dose (g/day)
0 15 30 0 15 30
Glucose (mg/dL)* 100.0 (12.3) 98.3 (9.4) 98.2 (13.0) 87.9 (4.5) 86.9 (6.6) 91.6 (8.5)
Insulin (μIU/ml)** 10.3 (4.6) 9.8 (4.6) 9.6 (6.9) 4.0 (1.8) 4.7 (2.0) 4.6 (1.4)
SI [(×10
-4 min-1 (μIU/ml)]*** 3.80 (1.54) 3.61 (1.60) 4.68 (1.71) 10.59 (5.77) 8.73 (3.61) 8.56 (2.95)
AIRg (μIU/mlx10 min) 510.6 (378.9) 438.1 (342.8) 582.1 (524.4) 380.0 (339.4) 344.1 (257.3) 403.3 (308.6)
DI 2000.2 (2221.0) 1444.7 (1197.6) 2680.8 (2913.2) 3342.9 (2507.4) 2746.7 (2132.2) 3470.9 (2992.3)
SG (min
-1) 0.020 (0.015) 0.015 (0.008) 0.021 (0.013) 0.022 (0.007) 0.027 (0.014) 0.023 (0.011)
Total Chol. (mg/dL) 187.6 (38.3) 181.2 (24.4) 190.4 (37.4) 179.6 (32.2) 182.4 (34.1) 190.8 (41.9)
HDL-C (mg/dL) 59.0 (18.0) 58.8 (9.6) 56.9 (14.3) 61.9 (8.1) 62.7 (8.9) 62.9 (12.9)
TG (mg/dL) 111.7 (47.9) 111.8 (50.8) 118.2 (59.1) 83.7 (19.6) 79.1 (27.0) 96.1 (31.1)
Adiponectin (μg/mL) 11.4 (5.7) 11.4 (4.9) 11.5 (5.4) 16.2 (4.6) 16.1 (4.3) 17.7 (6.8)
*P < 0.05, **P < 0.001 for IR vs IS at dose = 0 g/day
***P < 0.05 for dose effect within the IR sub-group. The 30 g/day dose differed from the 15 g/day dose (P < 0.05) and tended to differ from the 0 g/day dose
(P = 0.068)
IR insulin resistant [SI value <7.8 ×10
-4 min-1 / (μIU/ml)]
IS insulin sensitive [SI value ≥7.8 ×10
-4 min-1 / (μIU/ml)]
SI insulin sensitivity by minimal model
AIRg acute insulin response to glucose
DI disposition index (dimensionless)
SG glucose effectiveness
TG triglycerides
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more extensively characterize the site of RS action, and
determine whether the site of action differs with the
metabolic phenotype of the participants.
Strengths of this study were the double-blind, random-
ized, placebo-controlled cross-over design; inclusion of
African-American women, a group at disproportionate
risk for type 2 diabetes; testing during only the follicular
phase of the menstrual cycle; administration of two
doses of RS; and administration of the RS as a snack
food, which increases the translational potential of the
results. The main limitation was that many of the
women did not complete all three arms of the study.
This was a demanding study, requiring women to commit
to almost 6 months of involvement, with at least 12 weeks
of product consumption, and three intravenous glucose
tolerance tests. In addition, some women tired of consum-
ing two servings of cookies each day; a greater variety of
snack choices may have increased adherence. The small
sample size made interpretation of sub-group analyses dif-
ficult; a larger sample size is needed to more closely exam-
ine the response of sub-groups based on insulin sensitivity
status, menopausal status, and ethnicity/race.
Conclusions
In conclusion, among IR women, consumption of RS at
a dose of 30 g/d in the form of a snack food item was as-
sociated with improved insulin sensitivity. RS may be an
appropriate dietary ingredient to improve insulin sensi-
tivity in women, particularly those at elevated risk for
type 2 diabetes, such as African-American and post-
menopausal women.
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